KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)DivestmentsDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuances
Ratios

Steris (STE) Long-Term Debt Issuances (2020 - 2021)

Steris' quarterly Long-Term Debt Issuances came in at $650.0 million in Q2 2021, up 218.18% quarter-over-quarter from -$550.0 million in Q1 2021.

Steris has reported Long-Term Debt Issuances for 2 years, with the latest figure at $650.0 million in Q2 2021.

  • For the quarter ending Q2 2021, Long-Term Debt Issuances changed N/A year-over-year to $650.0 million; the trailing twelve-month figure through Mar 2022 stood at $650.0 million (changed N/A YoY), and the FY2022 full-year result was $650.0 million, changed N/A from the prior year.
  • Long-Term Debt Issuances for Q2 2021 stood at $650.0 million, up from -$550.0 million in the prior quarter.
  • The five-year high for Long-Term Debt Issuances was $650.0 million in Q2 2021, with the low at -$550.0 million in Q1 2021.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Issuances (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 19.86 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn -
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn 11.71 Mn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn 1.15 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn -
10 Zimmer Biomet Holdings 16.17 Bn 15.75 Bn 1.51 Bn -

Historic Data

Download Data 🔒
DateValue
Sep 30, 2021 700.00 Mn
Sep 30, 2021 700.00 Mn
Jun 30, 2021 650.00 Mn
Jun 30, 2021 650.00 Mn
Mar 31, 2021 -550.00 Mn
Mar 31, 2021 -550.00 Mn
Dec 31, 2020 550.00 Mn
Dec 31, 2020 550.00 Mn